Literature DB >> 18788906

Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy.

Juan Li1, Wunchang Sun, Bing Wang, Xiao Xiao, Xiang-Qin Liu.   

Abstract

Inteins catalyze protein splicing in a fashion similar to how self-splicing introns catalyze RNA splicing. Splitinteins catalyze precise ligation of two separate polypeptides through trans-splicing in a highly specific manner. Here we report a method of using protein trans-splicing to circumvent the packaging size limit of gene therapy vectors. To demonstrate this method, we chose a large dystrophin gene and an adeno-associated viral (AAV) vector, which has a small packaging size. A highly functional 6.3-kb Becker-form dystrophin cDNA was broken into two pieces and modified by adding appropriate split-intein coding sequences, resulting in splitgenes sufficiently small for packaging in AAV vectors. The two split-genes, after codelivery into target cells, produced two polypeptides that spontaneously trans-spliced to form the expected Becker-form dystrophin protein in cell culture in vitro. Delivering the split-genes by AAV1 vectors into the muscle of a mouse model of Duchenne muscular dystrophy rendered therapeutic gene expression and benefits.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18788906      PMCID: PMC2940629          DOI: 10.1089/hum.2008.009

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  28 in total

1.  A DnaB intein in Rhodothermus marinus: indication of recent intein homing across remotely related organisms.

Authors:  X Q Liu; Z Hu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility.

Authors:  M Koenig; L M Kunkel
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

3.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy.

Authors:  X Xiao; J Li; Y P Tsao; D Dressman; E P Hoffman; J F Watchko
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.

Authors:  S B England; L V Nicholson; M A Johnson; S M Forrest; D R Love; E E Zubrzycka-Gaarn; D E Bulman; J B Harris; K E Davies
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

6.  Recombinant adeno-associated virus for muscle directed gene therapy.

Authors:  K J Fisher; K Jooss; J Alston; Y Yang; S E Haecker; K High; R Pathak; S E Raper; J M Wilson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

7.  Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice.

Authors:  R O Snyder; S K Spratt; C Lagarde; D Bohl; B Kaspar; B Sloan; L K Cohen; O Danos
Journal:  Hum Gene Ther       Date:  1997-11-01       Impact factor: 5.695

8.  A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.

Authors:  R Sarkar; W Xiao; H H Kazazian
Journal:  J Thromb Haemost       Date:  2003-02       Impact factor: 5.824

9.  Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice.

Authors:  S F Phelps; M A Hauser; N M Cole; J A Rafael; R T Hinkle; J A Faulkner; J S Chamberlain
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

10.  Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter.

Authors:  T R Flotte; S A Afione; R Solow; M L Drumm; D Markakis; W B Guggino; P L Zeitlin; B J Carter
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.157

View more
  40 in total

Review 1.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  Highly efficient and more general cis- and trans-splicing inteins through sequential directed evolution.

Authors:  Julia H Appleby-Tagoe; Ilka V Thiel; Yi Wang; Yanfei Wang; Henning D Mootz; Xiang-Qin Liu
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

Review 3.  Group I introns and inteins: disparate origins but convergent parasitic strategies.

Authors:  Rahul Raghavan; Michael F Minnick
Journal:  J Bacteriol       Date:  2009-08-07       Impact factor: 3.490

4.  Split Inteins: Nature's Protein Ligases.

Authors:  Neel H Shah; Tom W Muir
Journal:  Isr J Chem       Date:  2011-11-01       Impact factor: 3.333

5.  Inteins: Nature's Gift to Protein Chemists.

Authors:  Neel H Shah; Tom W Muir
Journal:  Chem Sci       Date:  2014       Impact factor: 9.825

6.  Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts.

Authors:  Jian Ding; Zhi-Qiang Lin; Jian-Ming Jiang; Christine E Seidman; Jonathan G Seidman; William T Pu; Da-Zhi Wang
Journal:  J Vis Exp       Date:  2016-12-17       Impact factor: 1.355

Review 7.  Nature's recipe for splitting inteins.

Authors:  A Sesilja Aranko; Alexander Wlodawer; Hideo Iwaï
Journal:  Protein Eng Des Sel       Date:  2014-08       Impact factor: 1.650

Review 8.  Emerging Gene Therapies for Genetic Hearing Loss.

Authors:  Hena Ahmed; Olga Shubina-Oleinik; Jeffrey R Holt
Journal:  J Assoc Res Otolaryngol       Date:  2017-08-16

Review 9.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Authors:  Dan Wang; Feng Zhang; Guangping Gao
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

10.  Intein-mediated cytoplasmic reconstitution of a split toxin enables selective cell ablation in mixed populations and tumor xenografts.

Authors:  Vedud Purde; Elena Kudryashova; David B Heisler; Reena Shakya; Dmitri S Kudryashov
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.